Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6268479A · kind A · utility
16Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 1997 |
| Grant date | Jul 31, 2001 |
| Priority date | — |
| Expiry date | Mar 12, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an isolated nucleic acid encoding an endoplasmic reticulum associated amyloid-beta peptide binding (ERAB) polypeptide. The ERAB polypeptide may comprise human ERAB polypeptide. The present invention provides a purified ERAB polypeptide, as well as a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent in amount effective to inhibit ERAB polypeptide binding to amyloid-beta peptide so as to thereby treat the neurodegenerative condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.